Instituto de Investigación Sanitaria Biodonostia-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2015

  1. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627

2013

  1. Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6

    PLoS ONE, Vol. 8, Núm. 4

  2. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

    Journal of Medical Genetics, Vol. 50, Núm. 1, pp. 25-33

2012

  1. ANKRD55 and DHCR7 are novel multiple sclerosis risk loci

    Genes and Immunity, Vol. 13, Núm. 3, pp. 253-257

  2. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990

  3. Replication study of 10 genes showing evidence for association with multiple sclerosis: Validation of TMEM39A, IL12B and CLBL genes

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 959-965

2011

  1. Replication of top markers of a genome-wide association study in multiple sclerosis in Spain

    Genes and Immunity, Vol. 12, Núm. 2, pp. 110-115

2010

  1. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis

    Genes and Immunity, Vol. 11, Núm. 5, pp. 439-445

  2. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain

    Journal of Neuroimmunology, Vol. 223, Núm. 1-2, pp. 100-103